Contrast agents for quantitative MicroCT of lung tumors in mice

Comparative Medicine

Volumn 63, Issue 6, 2013, Pages 482-490

  Lalwani, Kush ^a   Giddabasappa, Anand ^a   Li, Danan ^b   Olson, Peter ^b   Simmons, Brett ^b   Shojaei, Farbod ^b   Van Arsdale, Todd ^b   Christensen, James ^b   Jackson Fisher, Amy ^b   Wong, Anthony ^c   Lappin, Patrick B ^c   Eswaraka, Jeetendra ^a  

^a Comparative Medicine ^*  (United States)

^b Oncology Research Unit   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; CRIZOTINIB; IODINATED CONTRAST MEDIUM; IODINATED LIPID; IOPAMIDOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG EFFICACY; HISTOPATHOLOGY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; QUANTITATIVE ANALYSIS; THERAPY EFFECT; TUMOR VOLUME;

ANIMALS; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; X-RAY MICROTOMOGRAPHY;

EID: 84892619084     PISSN: 15320820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Badea CT, Athreya KK, Espinosa G, Clark D, Ghafoori AP, Li Y, Kirsch DG, Johnson GA, Annapragada A, Ghaghada KB. 2012. Computed tomography imaging of primary lung cancer in mice using a liposomal-iodinated contrast agent. PLoS ONE 7:e34496.
2. Blasdale C, Charlton FG, Weatherhead SC, Ormond P, Lawrence CM. 2010. Effect of tissue shrinkage on histological tumour-free margin after excision of basal cell carcinoma. Br J Dermatol 162:607-610.
3. Boll H, Nittka S, Doyon F, Neumaier M, Marx A, Kramer M, Groden C, Brockmann MA. 2011. MicroCT based experimental liver imaging using a nanoparticulate contrast agent: a longitudinal study in mice. PLoS ONE 6:e25692.
4. Carlson SK, Classic KL, Bender CE, Russell SJ. 2007. Small animal absorbed radiation dose from serial microcomputed tomography imaging. Mol Imaging Biol 9:78-82.
5. Caulo A, Mirsadraee S, Maggi F, Leccisotti L, van Beek EJ, Bonomo L. 2012. Integrated imaging of non-small cell lung cancer recurrence: CT and PET-CT findings, possible pitfalls and risk of recurrence criteria. Eur Radiol 22:588-606.
6. Cavanaugh D, Johnson E, Price RE, Kurie J, Travis EL, Cody DD. 2004. In vivo respiratory-gated microCT imaging in small-animal oncology models. Mol Imaging 3:55-62.
7. Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, Liu Y, Tupper T, Ouyang J, Li J, Gao P, Woo MS, Xu C, Yanagita M, Altabef A, Wang S, Lee C, Nakada Y, Pena CG, Sun Y, Franchetti Y, Yao C, Saur A, Cameron MD, Nishino M, Hayes DN, Wilkerson MD, Roberts PJ, Lee CB, Bardeesy N, Butaney M, Chirieac LR, Costa DB, Jackman D, Sharpless NE, Castrillon DH, Demetri GD, Janne PA, Pandolfi PP, Cantley LC, Kung AL, Engelman JA, Wong KK. 2012. A murine lung cancer coclinical trial identifies genetic modifiers of therapeutic response. Nature 483:613-617.
8. Chouker A, Lizak M, Schimel D, Helmberger T, Ward JM, Despres D, Kaufmann I, Bruns C, Lohe F, Ohta A, Sitkovsky MV, Klaunberg B, Thiel M. 2008. Comparison of Fenestra VC contrast-enhanced computed tomography imaging with gadopentetate dimeglumine and ferucarbotran magnetic resonance imaging for the in vivo evaluation of murine liver damage after ischemia and reperfusion. Invest Radiol 43:77-91.
9. Christensen JG. 2011. Proof of principle for crizotinib in anaplastic lymphoma kinase-positive malignancies was achieved in ALKpositive nonclinical models. Mol Cancer Ther 10:2024.
10. Cui JJ, Tran-Dube M, Shen H, Nambu M, Kung PP, Pairish M, Jia L, Meng J, Funk L, Botrous I, McTigue M, Grodsky N, Ryan K, Padrique E, Alton G, Timofeevski S, Yamazaki S, Li Q, Zou H, Christensen J, Mroczkowski B, Bender S, Kania RS, Edwards MP. 2011. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 54: 6342-6363.
11. Doki Y, Murakami K, Yamaura T, Sugiyama S, Misaki T, Saiki I. 1999. Mediastinal lymph node metastasis model by orthotopic intrapulmonary implantation of Lewis lung carcinoma cells in mice. Br J Cancer 79:1121-1126.
12. DuPage M, Dooley AL, Jacks T. 2009. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 4:1064-1072.
13. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, Garcia-Echeverria C, Weissleder R, Mahmood U, Cantley LC, Wong KK. 2008. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14:1351-1356.
14. Frese KK, Tuveson DA. 2007. Maximizing mouse cancer models. Nat Rev Cancer 7:654-658.
15. Fushiki H, Kanoh-Azuma T, Katoh M, Kawabata K, Jiang J, Tsuchiya N, Satow A, Tamai Y, Hayakawa Y. 2009. Quantification of mouse pulmonary cancer models by microcomputed tomography imaging. Cancer Sci 100:1544-1549.
16. Gavrielides MA, Kinnard LM, Myers KJ, Petrick N. 2009. Noncalcified lung nodules: volumetric assessment with thoracic CT. Radiology 251:26-37.
17. Haines BB, Bettano KA, Chenard M, Sevilla RS, Ware C, Angagaw MH, Winkelmann CT, Tong C, Reilly JF, Sur C, Zhang W. 2009. A quantitative volumetric microcomputed tomography method to analyze lung tumors in genetically engineered mouse models. Neoplasia 11:39-47.
18. Hasegawa M, Sone S, Takashima S, Li F, Yang ZG, Maruyama Y, Watanabe T. 2000. Growth rate of small lung cancers detected on mass CT screening. Br J Radiol 73:1252-1259.
19. Herbst RS, Heymach JV, Lippman SM. 2008. Lung cancer. N Engl J Med 359:1367-1380.
20. Hirst GL, Balmain A. 2004. Forty years of cancer modelling in the mouse. Eur J Cancer 40:1974-1980.
21. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, Jacks T, Tuveson DA. 2001. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15:3243-3248.
22. Jackson MA, Lea I, Rashid A, Peddada SD, Dunnick JK. 2006. Genetic alterations in cancer knowledge system: analysis of gene mutations in mouse and human liver and lung tumors. Toxicol Sci 90:400-418.
23. Jaffe CC. 2006. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 24:3245-3251.
24. Kennel SJ, Davis IA, Branning J, Pan H, Kabalka GW, Paulus MJ. 2000. High-resolution computed tomography and MRI for monitoring lung tumor growth in mice undergoing radioimmunotherapy: correlation with histology. Med Phys 27:1101-1107.
25. Kirsch DG, Grimm J, Guimaraes AR, Wojtkiewicz GR, Perez BA, Santiago PM, Anthony NK, Forbes T, Doppke K, Weissleder R, Jacks T. 2010. Imaging primary lung cancers in mice to study radiation biology. Int J Radiat Oncol Biol Phys 76:973-977.
26. Kucherlapati R. 2012. Genetically modified mouse models for biomarker discovery and preclinical drug testing. Clin Cancer Res 18:625-630.
27. Moro M, Bertolini G, Tortoreto M, Pastorino U, Sozzi G, Roz L. 2012. Patient-derived xenografts of non-small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer stem cells. J Biomed Biotechnol 2012:568567.
28. Osborne DR, Yan S, Stuckey A, Pryer L, Richey T, Wall JS. 2012. Characterization of X-ray dose in murine animals using microCT, a new low-dose detector and nanodot dosimeters. PLoS ONE 7:e49936.
29. Schambach SJ, Bag S, Schilling L, Groden C, Brockmann MA. 2010. Application of microCT in small animal imaging. Methods 50:2-13.
30. Simmons BH, Lee JH, Lalwani K, Giddabasappa A, Snider BA, Wong A, Lappin PB, Eswaraka J, Kan JL, Christensen JG, Shojaei F. 2012. Combination of a MEK inhibitor at sub-MTD with a PI3K/ mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice. Cancer Chemother Pharmacol 70:213-220.
31. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H. 2007. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-566.
32. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. 2000. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216.
33. Tidwell VK, Garbow JR, Krupnick AS, Engelbach JA, Nehorai A. 2012. Quantitative analysis of tumor burden in mouse lung via MRI. Magn Reson Med 67:572-579.
34. Winkelmann CT, Figueroa SD, Rold TL, Volkert WA, Hoffman TJ. 2006. Microimaging characterization of a B16-F10 melanoma metastasis mouse model. Mol Imaging 5:105-114.